xRead - September 2022

Wise et al.

Page 387

Author Manuscript Author Manuscript Author Manuscript Author Manuscript Symptom score, medication use

Study Year LOE Study design Study groups Clinical endpoint Conclusion Welsh et al. 1364 1987 2b RCT, blinded 1 BDP 2 sprays BID, 336 μ g/day;

All medications were better than placebo. DSCG was the least effective.

Nasal symptoms Budesonide was better than DSCG. Symptom score, medication use

BDP performed better than DSCG. No difference in rescue medications.

Nasal symptoms BDP performed better than DSCG.

Nasal symptoms BV performed better than DSCG.

symptoms. The 2 medications performed the same for nPIF.

Nasal symptoms, nPIF BV performed better than DSCG for

2 Flunisolide 2 sprays BID, 200 μ g/day;

2 DSCG 5.2 mg, 5 times per day (n = 21) Morrow-Brown et al. 1366 1984 2b RCT, no placebo SAR, 11–71 years old: 1 BDP 2 sprays BID, 400 μ g/day (n = 47); no placebo 1 BDP 50 μ g QID;

1 Budesonide 200 μ g BID (n = 22);

1 DSCG 80 μ g, 6 times per day (n = 14); 2 BV 100 μ g BID (n = 18)

Wilson & Walker 1368 1976 2b RCT, no placebo SAR, adults: 1 DSCG 10 mg QID (n = 10); 2 BV 100 μ g BID (n = 10) placebo SAR, adults:

3 DSCG 1 spray QID, 41.6 mg/day; 4 Placebo

2 DSCG 2.6 mg, 6 times per day (n = 39) 2 DSCG 10 mg QID

SAR, 15–55 years old:

PAR, 13–45 years old (n = 14):

placebo

Bjerrum & Illum 1365 1985 2b DBRCT, no

Tandon & Strahan 1357 1980 2b DBRCT, crossover,

Frankland & Walker 1369 1975 2b DBRCT, no

BDP = beclomethasone dipropionate; BID = 2 times daily; BV = betamethasone valerate; DBRCT = double-blind randomized controlled trial; DSCG = disodium cromoglycate; FP = fluticasone propionate; LOE = level of evidence; MF = mometasone furoate; nPIF = nasal peak inspiratory flow; PAR = perennial allergic rhinitis; QD = once daily; QID = 4 times daily; RCT = randomized controlled trial; SAR = seasonal allergic rhinitis.

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.